perspectivetherapeutics.com (CATX): Long-Term Debt to Capital Ratio

Perspective Tx - graphic logo of issuer CATX

Current price action for Perspective Therapeutics (CATX) shows figures at 0.01. The issuer's operations are independent of market cycles, as demand for tumor treatment remains stable, with growth driven solely by successful test results. The business is based on the development of radiopharmaceuticals, where patents and the complexity of isotope delivery protect its niche. However, a lack of profitability and high R&D expenses are leading to capital depletion.

CATX - Perspective Tx Long-Term Debt to Equity over the range 06/21/2023 - 10/29/2026

Perspective Tx (CATX) - metric breakdowns and financial figures

- price and consensus price forecast:
Market Price Perspective Therapeutics Inc|CATX - Price Target Chart
- market capitalization data:
Market Capitalization Perspective Therapeutics, Inc.|CATX - Enterprise Value
- book capitalization data:
Accounting Value per Share Perspective Therapeutics|CATX - Company Book Value|Market-to-Book Ratio perspectivetherapeutics.com|CATX - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Perspective Therapeutics|CATX - Long-Term Debt to Equity|Current Liabilities to Capital Perspective Therapeutics Inc|CATX - Company Aggregate Debts|Debt to Net Assets Perspective Therapeutics, Inc.|CATX - Company Long-Term Liabilities|Short-Term Debt Perspective Therapeutics
Fundamental company valuation:CATX perspectivetherapeutics.com
Brand item of Perspective Therapeutics, Inc.

Analyzing the business scale of Perspective Therapeutics (CATX) through changes in long-term debt-to-equity allows for an assessment of the stability of a company with no commercial products. This ratio compares liabilities with a maturity of over one year to the market value of assets, determining the balance between the issuer's financial reliability and the efficiency of using borrowed capital to accelerate clinical development.

Who Perspective Therapeutics competes with

Long-Term Liabilities to Capital GERN|Long-Term Debt to Equity Nanobiotix Corp NBTX|Long-Term Debt to Capital Ratio Bicycle Corp (BCYC)|CytomX Therapeutics - Long-Term Debt to Capital|Genelux Corp. - Long-Term Debt to Equity Ratio|MOLN (Molecular Partners) - Long-Term Debt to Equity|ONCY: Long-Term Liabilities to Capital|lisata.com (LSTA) - Long-Term Debt to Equity|MBRX (Moleculin Biotech) - Long-Term Debt to Equity|Long-Term Debt to Equity GRTX (Galera Therapeutics Inc.)|Long-Term Liabilities to Capital mtem.com